Relmada Therapeutics Inc (NASDAQ: RLMD) on Friday, soared 4.98% from the previous trading day, before settling in for the closing price of $0.27. Within the past 52 weeks, RLMD’s price has moved between $0.24 and $6.63.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 16.46%. With a float of $25.28 million, this company’s outstanding shares have now reached $30.17 million.
Let’s determine the extent of company efficiency that accounts for 20 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Relmada Therapeutics Inc (RLMD) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Relmada Therapeutics Inc is 16.22%, while institutional ownership is 27.98%. The most recent insider transaction that took place on Sep 11 ’24, was worth 153,707. In this transaction Chief Executive Officer of this company bought 51,407 shares at a rate of $2.99, taking the stock ownership to the 384,024 shares. Before that another transaction happened on Sep 09 ’24, when Company’s Chief Executive Officer bought 55,579 for $2.71, making the entire transaction worth $150,619. This insider now owns 299,603 shares in total.
Relmada Therapeutics Inc (RLMD) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 16.46% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 25.49% during the next five years compared to -2.94% drop over the previous five years of trading.
Relmada Therapeutics Inc (NASDAQ: RLMD) Trading Performance Indicators
Relmada Therapeutics Inc (RLMD) is currently performing well based on its current performance indicators. A quick ratio of 6.89 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.87, a number that is poised to hit -0.71 in the next quarter and is forecasted to reach -1.15 in one year’s time.
Technical Analysis of Relmada Therapeutics Inc (RLMD)
Looking closely at Relmada Therapeutics Inc (NASDAQ: RLMD), its last 5-days average volume was 0.44 million, which is a drop from its year-to-date volume of 1.24 million. As of the previous 9 days, the stock’s Stochastic %D was 57.54%. Additionally, its Average True Range was 0.03.
During the past 100 days, Relmada Therapeutics Inc’s (RLMD) raw stochastic average was set at 1.23%, which indicates a significant decrease from 43.78% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 55.93% in the past 14 days, which was lower than the 252.30% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3539, while its 200-day Moving Average is $2.3174. However, in the short run, Relmada Therapeutics Inc’s stock first resistance to watch stands at $0.2983. Second resistance stands at $0.3100. The third major resistance level sits at $0.3272. If the price goes on to break the first support level at $0.2694, it is likely to go to the next support level at $0.2522. Now, if the price goes above the second support level, the third support stands at $0.2405.
Relmada Therapeutics Inc (NASDAQ: RLMD) Key Stats
Market capitalization of the company is 8.64 million based on 30,174K outstanding shares. Right now, sales total 0 K and income totals -98,790 K. The company made 0 K in profit during its latest quarter, and -21,730 K in sales during its previous quarter.
